Imeglimin preserves islet ß-cell mass in Type 2 diabetic ZDF rats.

Hallakou-Bozec, Sophie; Kergoat, Micheline; Moller, David E; Bolze, Sébastien

Hallakou-Bozec, Sophie; Kergoat, Micheline; Moller, David E; Bolze, Sébastien.

Affiliation

Hallakou-Bozec S; Poxel SA, Lyon, France.
Kergoat M; Metabrain Research, Maisons-Alfort, France.
Moller DE; Poxel SA, Lyon, France.
Bolze S; Poxel SA, Lyon, France.

Endocrinol Diabetes Metab ; 4(2): e00193, 2021 04.

Article in En | MEDLINE | ID: mdl-33855202

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Diabetes Mellitus, Type 2/pathology; Insulin-Secreting Cells/pathology; Triazines/pharmacology; Triazines/therapeutic use; Animals; Apoptosis/drug effects; Cell Proliferation/drug effects; Cells, Cultured; Diabetes Mellitus, Type 2/metabolism; Disease Models, Animal; Glucose Intolerance/drug therapy; Hyperglycemia/drug therapy; Insulin/metabolism; Insulin Secretion/drug effects; Insulin-Secreting Cells/metabolism; Male; Rats, Zucker

Key words

animal models; imeglimin; islet; new therapies

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Triazines / Diabetes Mellitus, Type 2 / Insulin-Secreting Cells Limits: Animals Language: En Journal: Endocrinol Diabetes Metab Year: 2021 Type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google